

Sun Pharmaceutical Industries Ltd.

Acme Plaza, Andheri - Kurla Road,
Andheri (East), Mumbai - 400 059, INDIA.
Tel. : (91-22) 2823 0102, 2821 2128, 6696 9696, 6696 9600
Fax : (91-22) 2821 2010
www.sunpharma.com
CIN : L24230GJ1993PLC019050



March 30, 2015

National Stock Exchange of India Ltd,
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (East),
Mumbai - 400 051.

BSE Limited,
Market Operations Dept.
P. J. Towers,
Dalal Street,
Mumbai - 400 001.

Dear Sirs,

Re: Disclosure under Regulation 10(6) of the SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011

Please find enclosed herewith the disclosure in the prescribed Form under Regulation 10(6) of the SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011, being filed on merger of Ranbaxy Laboratories Limited with the Company being effective on March 24, 2015.

Thanking you,

For Sun Pharmaceutical Industries Limited

Ashok Bhuta
Compliance Officer

Encl: As above

Disclosures under Regulation 10(6) - Report to Stock Exchanges in respect of any acquisition made in reliance upon exemption provided for in Regulation 10 of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

1.	Name of the Target Company (TC)	Ranbaxy Laboratories Limited			
2.	Name of the acquirer(s)	Sun Pharmaceutical Industries Limited			
3.	Name of the stock exchange where shares of the TC are listed	BSE Limited National Stock Exchange of India Limited			
4.	Details of the transaction including rationale, if any, for the transfer/ acquisition of shares.	Pursuant to Scheme of Arrangement for merger of Ranbaxy Laboratories Limited into Sun Pharmaceutical Industries Limited being effective on March 24, 2015			
5.	Relevant regulation under which the acquirer is exempted from making open offer.	Regulation 10 (1)(d)(ii)			
6.	Whether disclosure of proposed acquisition was required to be made under regulation 10 (5) and if so, - whether disclosure was made and whether it was made within the timeline specified under the regulations. - date of filing with the stock exchange.	Not Applicable			
7.	Details of acquisition	Disclosures required to be made under regulation 10(5)		Whether the disclosures under regulation 10(5) are actually made	
	a. Name of the transferor / seller	Pursuant to Scheme of Arrangement for merger of Ranbaxy Laboratories Limited into Sun Pharmaceutical Industries Limited being effective on March 24, 2015			
	b. Date of acquisition				
	c. Number of shares/ voting rights in respect of the acquisitions from each person mentioned in 7(a) above				
	d. Total shares proposed to be acquired / actually acquired as a % of diluted share capital of TC				
	e. Price at which shares are proposed to be acquired / actually acquired				
8.	Shareholding details	Pre-Transaction		Post-Transaction	
		No. of shares held	% w.r.t total share capital of TC	No. of shares held	% w.r.t total share capital of TC
	a Sun Pharmaceutical Industries Limited	0	0	0	0
	b Silverstreet Developers LLP	6967542	1.64	0#	0

#Due to merger of Ranbaxy Laboratories with Sun Pharmaceutical Industries Limited.

Note:

- (*) Shareholding of each entity shall be shown separately and then collectively in a group.
- The above disclosure shall be signed by the acquirer mentioning date & place. In case, there is more than one acquirer, the report shall be signed either by all the persons or by a person duly authorized to do so on behalf of all the acquirers.

For Sun Pharmaceutical Industries Limited

A I R

**Ashok Bhuta
Compliance Officer**


